Grufity logo
Grufity logo

Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio

$11.51Billion | No. of Holdings #84

RA CAPITAL MANAGEMENT, L.P. Performance

2026 Q2+8.02%
YTD+7.75%
2025+28.52%

About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings

RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in Boston, MA. On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $11.5 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , , RYTM. The fund has invested 23.8% of it's portfolio in ASCENDIS PHARMA A/S and 6.9% of portfolio in PARABILIS MEDICINES INC. <br><br> The fund managers got completely rid off ASCENDIS PHARMA A/S - ADR (ASND), DIANTHUS THERAPEUTICS INC and PRAXIS PRECISION MEDICINES I (PRAX) stocks. They significantly reduced their stock positions in WEREWOLF THERAPEUTICS INC (HOWL), VOR BIOPHARMA INC (VOR) and NUVALENT INC-A (NUVL). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in ASCENDIS PHARMA A/S, INTELLIA THERAPEUTICS INC (NTLA) and SANA BIOTECHNOLOGY INC (SANA). The fund showed a lot of confidence in some stocks as they added substantially to ACLARIS THERAPEUTICS INC (ACRS), ARTIVA BIOTHERAPEUTICS INC and AVALO THERAPEUTICS INC (AVTX).
RA CAPITAL MANAGEMENT, L.P. Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$11.51Billion
  as of Aug 14, 2026

RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of 8.02% in the last quarter. In trailing 12 months, it's portfolio return was 67.88%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
ascendis pharma a/s2,742,280,000
parabilis medicines inc791,906,000
hemab therapeutics holdings286,811,000
abivax sa-adr150,925,000
oruka therapeutics inc147,951,000
intellia therapeutics inc76,595,600
definium therapeutics inc70,560,000
sana biotechnology inc65,437,500
New stocks bought by RA CAPITAL MANAGEMENT, L.P.

Additions

Ticker% Inc.
aclaris therapeutics inc86.99
artiva biotherapeutics inc82.23
avalo therapeutics inc50.84
acrivon therapeutics inc46.63
solid biosciences inc28.87
xencor inc7.7
rezolute inc2.89
bioage labs inc1.27
Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.

Reductions

Ticker% Reduced
werewolf therapeutics inc-64.26
vor biopharma inc-55.56
nuvalent inc-a-50.81
geron corp-32.87
adicet bio inc-21.14
edgewise therapeutics inc-19.52
aktis oncology inc-12.55
palatin technologies inc-11.25
RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock

Sold off

Ticker$ Sold
ascendis pharma a/s - adr-2,351,690,000
fulcrum therapeutics inc-46,433,900
sarepta therapeutics inc-84,920,500
design therapeutics inc-31,632,400
relmada therapeutics inc-20,513,700
dianthus therapeutics inc-219,177,000
olema pharmaceuticals inc-38,766,000
spyre therapeutics inc-81,794,500
RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks

Sector Distribution

RA CAPITAL MANAGEMENT, L.P. has about 58.9% of it's holdings in Others sector.

  • Others
  • Healthcare
Sector%
Others58.9
Healthcare40.4

Market Cap. Distribution

RA CAPITAL MANAGEMENT, L.P. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

  • UNALLOCATED
  • SMALL-CAP
  • MID-CAP
  • MICRO-CAP
Category%
UNALLOCATED58.9
SMALL-CAP18.3
MID-CAP18.2
MICRO-CAP3.4

Stocks belong to which Index?

About 31.8% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
Index%
Others68.2
RUSSELL 200031.8
Top 5 Winners (%)%
GHRS
gh research plc
90.9 %
ELYM
climb bio inc
90.4 %
CCCC
c4 therapeutics inc
77.6 %
anteris technologies global
77.5 %
KPTI
karyopharm therapeutics inc
75.4 %
Top 5 Winners ($)$
RYTM
rhythm pharmaceuticals inc
160.4 M
GHRS
gh research plc
98.2 M
EWTX
edgewise therapeutics inc
85.9 M
bicara therapeutics inc
71.1 M
ELYM
climb bio inc
70.0 M
Top 5 Losers (%)%
evommune inc
-42.2 %
HOWL
werewolf therapeutics inc
-38.5 %
lenz therapeutics inc
-37.9 %
PTN
palatin technologies inc
-35.9 %
CAPR
capricor therapeutics inc
-20.8 %
Top 5 Losers ($)$
TYRA
tyra biosciences inc
-77.6 M
WVE
wave life sciences ltd
-38.8 M
evommune inc
-33.9 M
spyglass pharma inc
-29.3 M
lenz therapeutics inc
-14.5 M

RA CAPITAL MANAGEMENT, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P. has 84 stocks in it's portfolio. About 60.4% of the portfolio is in top 10 stocks. TYRA proved to be the most loss making stock for the portfolio. RYTM was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.

$11.51BTotal Value
102Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P., last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S - Adr

Ascendis Pharma A/S - Adr

ASND
RA CAPITAL MANAGEMENT, L.P.'s holding in Ascendis Pharma A/S - Adr over time
0%0.00
$0.00
0%
decreased 100 percentsold off
DRUG
Bright Minds Biosciences Inc

Bright Minds Biosciences Inc

DRUG
RA CAPITAL MANAGEMENT, L.P.'s holding in Bright Minds Biosciences Inc over time
0.16%265,000
$18.60M
0.16%
unchanged 0 percentunchanged